Travere Therapeutics Announces Completion of Public Offering of Common Stock and Pre-Funded Warrants and Exercise in Full of Underwriters’ Option to Purchase Additional Shares

Rhea-AI Summary

Travere Therapeutics (Nasdaq: TVTX) has successfully completed its underwritten public offering, selling 9.7 million shares of common stock at $21.00 per share, along with 1.25 million pre-funded warrants at $20.9999 per warrant. The offering generated approximately $230 million in gross proceeds, including the full exercise of underwriters’ options. The shares were sold under a shelf registration statement effective since September 3, 2021, with Jefferies, J.P. Morgan, BofA Securities, and SVB Securities serving as joint book-running managers. This offering is part of Travere's strategy to enhance its financial position for future developments.

Positive

• Gross proceeds of approximately $230 million strengthen financial position.
• Successfully raised capital through the offering to support future developments.

Negative

• Dilution of existing shares due to the issuance of new shares.
• -

SAN DIEGO, March 03, 2023 (GLOBE NEWSWIRE) -- Travere Therapeutics, Inc. (Nasdaq: TVTX) today announced the completion of its previously announced underwritten public offering of 9,703,750 shares of its common stock at a price to the public of $21.00 per share and pre-funded warrants to purchase 1,250,000 shares of its common stock at a price to the public of $20.9999 per pre-funded warrant, including 1,428,750 shares sold pursuant to the exercise in full of the underwriters’ option to purchase additional shares. All of the shares were sold by Travere. Including the option exercise, the aggregate gross proceeds from the offering were approximately $230.0 million, before deducting the underwriting discounts and commissions and offering expenses.

Jefferies, J.P. Morgan, BofA Securities and SVB Securities acted as the joint book-running managers for the offering.

The shares of common stock described above were offered by Travere pursuant to a shelf registration statement filed by Travere with the Securities and Exchange Commission (SEC) that became automatically effective on September 3, 2021. A final prospectus supplement and accompanying prospectus related to the offering have been filed with the SEC and are available on the SEC’s website located at http://www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus related to this offering may be obtained from Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, NY 10022, by telephone at (877) 821-7388, or by email at Prospectus_Department@Jefferies.com; from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204, or by email at fi@jpmchase.com; from BofA Securities, NC1-004-03-43 200 North College Street, 3rd floor Charlotte, NC 28255-0001 Attention: Prospectus Department, or by email at dg.prospectus_requests@bofa.com; or from SVB Securities LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, or by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@svbsecurities.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Travere Therapeutics

At Travere Therapeutics we are in rare for life. We are a biopharmaceutical company that comes together every day to help patients, families and caregivers of all backgrounds as they navigate life with a rare disease. On this path, we know the need for treatment options is urgent – that is why our global team works with the rare disease community to identify, develop and deliver life-changing therapies. In pursuit of this mission, we continuously seek to understand the diverse perspectives of rare patients and to courageously forge new paths to make a difference in their lives and provide hope – today and tomorrow.

Contact:
Naomi Eichenbaum
Vice President, Investor Relations
888-969-7879
IR@travere.com

FAQ

What was the purpose of Travere Therapeutics' public offering?

The offering aimed to strengthen Travere's financial position for future developments.

How much capital did Travere Therapeutics raise from the recent stock offering?

Travere raised approximately $230 million from the offering.

What are the terms of the common stock and pre-funded warrants offering by Travere?

The offering included 9.7 million shares at $21.00 each and 1.25 million pre-funded warrants at $20.9999 each.

Who managed the underwritten public offering for Travere Therapeutics?

The offering was managed by Jefferies, J.P. Morgan, BofA Securities, and SVB Securities.

What impact will the stock offering have on shareholders of Travere Therapeutics?

The stock offering will result in dilution of existing shareholders due to the issuance of new shares.